Management Change
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and SALT LAKE CITY, 18 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Howard Doran, who has served as the Company's Chief Business Officer since September 2023, has been appointed as President, effective April 30, 2024. Thomas McLain, who has served as the Company's President since July 2019, is stepping down effective that date.
James McCullough, Renalytix CEO, said:
"We thank Tom for his many accomplishments in helping Renalytix achieve the tri-fecta of broad insurance coverage, FDA regulatory approval and real-world outcomes evidence that now positions KidneyIntelX for commercial adoption.
"Howard assumes the position of President to lead the global sales effort having now built our sales team from individuals with leading industry sales track records."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.